Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jun 11, 2026
Why Is Defiance Daily Target 2X Long ORCL ETF (ORCX) ETF Down -18% Today?

Why Is Defiance Daily Target 2X Long ORCL ETF (ORCX) ETF Down -18% Today?

Key Takeaways

  • ORCX is down approximately 18% in premarket trading on June 11, 2026, reflecting a near-double amplification of Oracle Corporation's (ORCL) roughly 9–10% premarket decline.
  • The primary catalyst is Oracle's fiscal Q4 2026 earnings report, which, despite beating Wall Street estimates, revealed a staggering $55.7 billion in capital expenditures and a new $40 billion capital raise plan that alarmed investors.
  • Negative free cash flow of -$23.7 billion for fiscal year 2026 and a $20 billion share offering announcement added dilution concerns that amplified the selloff.
  • As a 2x daily leveraged ETF tracking a single stock, ORCX mechanically doubles Oracle's daily price move, making it extremely sensitive to any sharp movement in ORCL.
  • Oracle's Q1 FY2027 guidance was seen as underwhelming relative to the scale of spending commitments, reinforcing near-term margin concerns.
  • Investors will be watching ORCL's ability to convert its $638 billion backlog and AI infrastructure investments into positive free cash flow in the quarters ahead.

Opening Summary

The Defiance Daily Target 2X Long ORCL ETF (ORCX) is a single-stock leveraged ETF designed to deliver two times (2x) the daily price return of Oracle Corporation (ORCL) through the use of swap agreements and derivatives. In premarket trading on June 11, 2026, ORCX has declined approximately 18%, directly reflecting ORCL's premarket drop of roughly 9–10% from its prior session closing price of $200.73, with Oracle shares indicated near $180 in early trading. The fund's dramatic pre-market loss is driven entirely by investor reaction to Oracle's fiscal Q4 2026 earnings release, which, despite posting beats on both revenue and earnings per share, disclosed capital expenditure levels and a new $40 billion capital raise that unsettled markets.

What Drove the ETF Move Today

Oracle's Q4 Earnings Beat — But the Spending Alarmed Wall Street

Oracle reported fiscal Q4 2026 adjusted EPS of $2.03, topping the consensus estimate of $1.96, while total revenue came in at $19.18 billion versus the $19.10 billion expected — a 21% year-over-year increase. Cloud Infrastructure (IaaS) revenue surged 93% to $5.8 billion, and the company's Remaining Performance Obligations (RPO) reached a remarkable $638 billion, far above the $595.67 billion Wall Street had anticipated, partly driven by a landmark deal with OpenAI. Yet the headline beats were quickly overshadowed by the capital commitment disclosures buried in the same earnings release.

Massive Capital Expenditures and Dilution Risk

Oracle disclosed that capital expenditures for fiscal year 2026 skyrocketed 162% year-over-year to $55.7 billion, exceeding analyst forecasts by approximately $5 billion. The company also announced plans to raise an additional $40 billion through a combination of debt and a newly revealed $20 billion equity share offering. This follows an already heavy fiscal 2026 capital raise of $43 billion in debt and $5 billion in equity. The prospect of significant shareholder dilution and continued deep negative free cash flow — reported at -$23.7 billion for the full fiscal year — triggered the sharp selloff in ORCL shares and, by mechanical leverage, an amplified decline in ORCX.

Negative Free Cash Flow and Near-Term Guidance

Investors were further unsettled by the near-term earnings outlook. While Oracle's Q1 FY2027 revenue growth is guided at 27–29% year-over-year and adjusted EPS is expected between $1.72 and $1.76 — slightly ahead of the $1.68 analyst estimate — these figures do not adequately offset concerns about the sustainability of spending at this scale. The capital-intensive AI data center build-out, which includes plans to bring nearly one gigawatt of computing capacity online in the current quarter alone, signals that negative free cash flow is likely to persist. Morgan Stanley reiterated its Equal Weight rating on ORCL with a $207 price target, reflecting cautious sentiment.

Which Holdings Contributed Most

ORCX holds concentrated exposure almost entirely through Oracle-linked swap agreements and a direct holding in ORCL common stock. The fund's portfolio consists primarily of Oracle Corp swaps with BMO and Credit Suisse counterparties, which together make up the leveraged exposure, alongside a direct ORCL equity position. Because the fund is explicitly structured to deliver 2x the daily performance of ORCL, every percentage point decline in Oracle's stock translates directly into approximately two percentage points of loss for ORCX. Today's move is therefore entirely attributable to Oracle's post-earnings selloff — there are no other holdings or diversification factors that could buffer the fund's performance.

Market Context and Trading Activity

The sector-wide impact of Oracle's announcement was visible across enterprise software peers, with SAP shares falling approximately 3% in sympathy as investors reassessed AI capital spending trends across the broader software industry. The broader technology sector faced modest headwinds, though Oracle's decline was notably sharper than the overall market tone. From a technical perspective, ORCL had been trading near its 30-day exponential moving average around $200, and the premarket gap lower to near $180 slices below the 100-day EMA at approximately $186, directly challenging the 61.8% Fibonacci retracement level at $178.99 — a key structural support zone. Given that ORCX is a leveraged single-stock product, volume in the fund itself is expected to be significantly elevated as traders and hedgers adjust positions in response to the underlying stock's sharp move.

Trending AI Robots

For traders looking to navigate volatile sessions like today's, Tickeron's Trending AI Robots page offers a curated selection of the platform's strongest-performing AI trading bots under current market conditions. Tickeron operates hundreds of AI-driven bots covering thousands of tickers across equities, ETFs, and leveraged funds, but only those demonstrating the most compelling performance metrics — factoring in strategy, timeframe, win rates, and recent returns — are featured in this trending section. Bots range from short-term momentum strategies to longer-duration trend-followers, each tailored to specific market environments. Whether you are managing exposure to high-volatility single-stock ETFs like ORCX or broader index products, exploring the Trending AI Robots section can help identify systematic approaches designed for today's fast-moving market conditions.

What Comes Next for ORCX

The forward outlook for ORCX is closely tied to how Oracle's stock recovers — or continues to deteriorate — as markets fully digest the earnings report during regular session trading on June 11. Investors will focus on Oracle's ability to demonstrate that its $638 billion RPO backlog, more than 50% of which is attributed to its OpenAI partnership, will translate into sustained revenue acceleration and, ultimately, a return to positive free cash flow. The $70 billion gross capital expenditure outlook for FY2027 means the dilution and debt risks that triggered today's selloff are not transient issues. Key factors to monitor include the pace of data center capacity deployment, the trajectory of IaaS revenue growth, interest rate conditions affecting Oracle's heavy debt load, and any updates to the OpenAI partnership. As a 2x leveraged daily-reset product, ORCX is subject to compounding effects over multiple sessions, meaning prolonged volatility in ORCL can produce decay that diverges significantly from a simple 2x multiple of Oracle's longer-term return. This instrument is designed for short-term trading, not long-term holding, and the risks are materially elevated in periods of high underlying volatility such as the current one.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitation

Related Ticker: ORCX

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


ORCX sees its Stochastic Oscillator ascends from oversold territory

On October 02, 2026, the Stochastic Oscillator for ORCX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 19 instances where the indicator left the oversold zone. In 19 of the 19 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +6.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where ORCX advanced for three days, in 79 of 84 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ORCX as a result. In 18 of 19 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for ORCX turned negative on September 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 12 similar instances when the indicator turned negative. In 11 of the 12 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

ORCX moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ORCX crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 2 of 3 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ORCX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

ORCX broke above its upper Bollinger Band on September 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Industry description

The investment seeks daily investment results, before fees and expenses, of two times (200%) the daily percentage change in the share price of Oracle Corporation (NYSE: ORCL). The fund is an actively managed exchange traded fund (“ETF”) that attempts to achieve two times (200%) the daily percentage change in the share price of the underlying security by employing derivatives, namely swap agreements and/or listed options contracts. The fund is non-diversified.
View a ticker or compare two or three
ORCX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Trading

Category
Trading--Leveraged Equity
Address
United States
Phone
N/A
Web
N/A
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.
I've always appreciated how Mastercard (MA) maintains a commanding position in the global payments industry, processing transactions across 3.4 billion cards at 150 million merchant locations worldwide. The network effects here create a formidable moat—increased adoption by issuers, acquirers, and consumers just reinforces its dominance. What stands out to me is how Mastercard is evolving beyond a pure processor into a services-first platform. Value-added services (VAS)—covering cybersecurity, data analytics, and consulting—are now approaching 40% of revenues and growing at double the rate of traditional payments.
MU shares are declining approximately -6.00% in premarket trading on April 2, 2026, pulling back to roughly $353.70 from the prior session's close of $376.27. The primary catalyst is a sweeping new round of tariff announcements from the Trump administration, dubbed by markets as "Liberation Day 2.0," which has sparked a broad risk-off selloff across technology and semiconductor stocks
Shares of Robinhood Markets are down approximately 6.15% in Thursday's intraday session, trading around $65.80 after closing at $70.11 on April 1, 2026. Wolfe Research delivered a sharp blow by cutting its price target on HOOD by 30%, citing persistent weakness in crypto trading volumes as a core drag on revenue.